Experts from the U.S. Food and Drug Administration (FDA) discuss important new drug information as well as urgent insights about approved drug products.
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (L...
FDA’s Role in Foreign Drug Manufacturing
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Ser...
Leonard H. Calabrese, DO
John R. Tesser, MD
Pinpointing the Top Questions about Biosimilars in Rheumatology
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
Stay current with the best on medical education
We’re glad to see you’re enjoying Prova Education…but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.